Furthermore, in vivo tumor models not only confirmed the potent anti-tumor efficacy of AP203, but also revealed that AP203 treatment can modulate the immunosuppressive tumor microenvironment, with evidence of cytotoxic CD8 + T cell expansion and Treg cell suppression. Here, CD8A is linked to neoplasm.